Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27583662 | 0.84 | DGAT1 (0.36) | TDP1ALDH1A1TSHR | |
| SCHEMBL29048959 | 0.83 | ALDH1A1 (0.54) | ALDH1A1TSHRFFAR3 | |
| SCHEMBL28145423 | 0.80 | CYP4F2 (0.42) | ALDH1A1SOAT1 | |
| SCHEMBL24780286 | 0.77 | SOAT1 (0.35) | TDP1ALDH1A1FFAR3SOAT1 | |
| SCHEMBL25477774 | 0.77 | ALDH1A1 (0.31) | ALDH1A1TSHRSOAT1 | |
| SCHEMBL8935690 | 0.76 | ALDH1A1 (0.35) | TDP1ALDH1A1TSHRFFAR3 | |
| SCHEMBL20865671 | 0.74 | ALOX15 (0.36) | TDP1ALDH1A1TSHR | |
| SCHEMBL9418812 | 0.70 | ALDH1A1 (0.31) | TDP1ALDH1A1TSHR | |
| SCHEMBL14217436 | 0.70 | HTT (0.31) | TDP1ALDH1A1TSHR | |
| SCHEMBL10837533 | 0.69 | CYP4F2 (0.40) | TDP1ALDH1A1TSHRFFAR3SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034196-A1 | ESTER DERIVATIVES OF N4-HYDROXYCYTIDINE AND USE THEREOF | SUZHOU SPRING-SEA BIO-PHARMACEUTICALS CO., LTD. (CN) | 2025-01-30 | — | — | US | disclosed |
| EP-4430055-A1 | ESTER DERIVATIVES OF N4-HYDROXYCYTIDINE AND USE THEREOF | Suzhou Spring-Sea Bio-Pharmaceuticals Co., Ltd. (CN) | 2024-09-18 | — | — | EP | disclosed |
| CN-117642410-A | Ester derivatives of N4-hydroxycytidine and uses thereof | 苏州春海生物医药有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-116583530-A | N 4 Ester derivatives of hydroxycytidine and their use | 苏州春海生物医药有限公司 | 2023-08-11 | — | — | CN | disclosed |
| WO-2022262845-A1 | ESTER DERIVATIVES OF N4-HYDROXYCYTIDINE AND USE THEREOF | SUZHOU SPRING-SEA BIO-PHARMACEUTICALS CO., LTD. (CN) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034196-A1 | ESTER DERIVATIVES OF N4-HYDROXYCYTIDINE AND USE THEREOF | DCTD, NUDT1, TYMP | TDP1 172/4885ALDH1A1 3272/4885TSHR 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.